{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.46","value":"-2.20"},{"groupId":"OG001","spread":"1.83","value":"-3.27"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"179"},{"groupId":"OG001","value":"125"}],"units":"Participants"}],"title":"Functional scale: Body image"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.00","value":"0.41"},{"groupId":"OG001","spread":"1.25","value":"-1.60"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"116"}],"units":"Participants"}],"title":"Functional scale:Sexual functioning"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.06","value":"6.06"},{"groupId":"OG001","spread":"2.51","value":"10.05"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"179"},{"groupId":"OG001","value":"126"}],"units":"Participants"}],"title":"Functional scale: Future perspective"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.00","value":"7.23"},{"groupId":"OG001","spread":"1.22","value":"6.98"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"125"}],"units":"Participants"}],"title":"Symptom scale: Systemic therapy side effects"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.89","value":"-2.10"},{"groupId":"OG001","spread":"1.09","value":"-0.96"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"181"},{"groupId":"OG001","value":"126"}],"units":"Participants"}],"title":"Symptom scale: Breast symptoms"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.29","value":"-0.45"},{"groupId":"OG001","spread":"1.59","value":"0.10"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"125"}],"units":"Participants"}],"title":"Symptom scale: Arm symptoms"}],"denoms":[{"counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"126"}],"units":"Participants"}],"description":"EORTC-QLQ-BR23 measured multi-item functional scales for body image, sexual functioning and future perspective and measured single item symptoms scales which assessed systemic therapy side effects, breast symptoms and arm symptoms. For functional scales, scores ranged from 0 to 100 where higher scores represented a better level of functioning. For symptoms scales, scores ranged from 0 to 100 where higher scores represented a greater degree of symptoms. LS Mean value of changing from baseline to short follow up was estimated from the mixed model that was controlled for Treatment, visit, Treatment\\*Visit and baseline.","dispersionType":"Standard Error","groups":[{"description":"Abemaciclib 150 mg administered orally every 12 hours on Days 1 to 28 of a 28-day cycle in combination with fulvestrant 500mg administered IM on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond. Participants received treatment until discontinuation were met.","id":"OG000","title":"Abemaciclib + Fulvestrant"},{"description":"Placebo administered orally every 12 hours on Days 1 to 28 of a 28-day cycle in combination with fulvestrant 500mg administered IM on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond. Participants received treatment until discontinuation were met.","id":"OG001","title":"Placebo + Fulvestrant"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"All randomized participants who received at least one dose of study drug with baseline and post-baseline EORTC QLQ-BR23 data at short term follow up for each BR23 items.","reportingStatus":"POSTED","timeFrame":"Baseline, Short Term Follow Up (Up To 31 Months)","title":"Change From Baseline to Short Term Follow up in Quality of Life Using the EORTC QLQ-BR23 (Breast) Questionnaire","type":"SECONDARY","unitOfMeasure":"Units on a scale"}